Adverse Effects

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Early survival data remain immature, with results suggesting the noncovalent BTK inhibitor could influence frontline treatment choices.